Chris Degnan, the Chief Financial Officer of $URGN, sold 2,203 shares of the company on 10-08-2025 for an estimated $37,120. We received data on the trade from a recent SEC filing. This was a sale of approximately 49.1% of their shares of this class of stock. Following this trade, they now own 2,280 shares of this class of $URGN stock.
$URGN Insider Trading Activity
$URGN insiders have traded $URGN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 3 sales selling 16,033 shares for an estimated $231,588.
- CHRIS DEGNAN (Chief Financial Officer) sold 2,203 shares for an estimated $37,120
- JASON DREW SMITH (General Counsel) sold 1,520 shares for an estimated $29,047
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$URGN Hedge Fund Activity
We have seen 85 institutional investors add shares of $URGN stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,360,524 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $59,739,178
- RA CAPITAL MANAGEMENT, L.P. removed 3,206,271 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,925,912
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,185,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $29,934,500
- VESTAL POINT CAPITAL, LP removed 2,152,957 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $29,495,510
- MORGAN STANLEY added 1,620,743 shares (+189.0%) to their portfolio in Q2 2025, for an estimated $22,204,179
- TORONTO DOMINION BANK added 1,441,368 shares (+82.4%) to their portfolio in Q2 2025, for an estimated $19,746,741
- JEFFERIES FINANCIAL GROUP INC. added 1,384,652 shares (+169.9%) to their portfolio in Q2 2025, for an estimated $18,969,732
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$URGN Analyst Ratings
Wall Street analysts have issued reports on $URGN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 08/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/11/2025
- D. Boral Capital issued a "Buy" rating on 08/07/2025
- Guggenheim issued a "Buy" rating on 06/13/2025
- Scotiabank issued a "Sector Outperform" rating on 06/13/2025
- Oppenheimer issued a "Outperform" rating on 06/03/2025
To track analyst ratings and price targets for $URGN, check out Quiver Quantitative's $URGN forecast page.
$URGN Price Targets
Multiple analysts have issued price targets for $URGN recently. We have seen 9 analysts offer price targets for $URGN in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 10/03/2025
- Kelsey Goodwin from Piper Sandler set a target price of $36.0 on 08/19/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $40.0 on 08/11/2025
- Kelsey Goodwin from Guggenheim set a target price of $30.0 on 06/13/2025
- George Farmer from Scotiabank set a target price of $47.0 on 06/13/2025
- Leland Gershell from Oppenheimer set a target price of $10.0 on 06/03/2025
- Paul Choi from Goldman Sachs set a target price of $3.0 on 05/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
